Skip to main content

Table 2 Characteristics of basket trials for disease-modifying agents in neurodegenerative disorders

From: The role of basket trials in drug development for neurodegenerative disorders

Drug Number of trials CADRO target NDDs included
ATH-1017 1 Neuroprotection PD, DLB
BIIB092 1 Tau extracellular transmission FTLD, CBD, CTE
Davunetide (AL-108, NAP) 1 Tau aggregation PSP, CBD, FTLD
Deferiprone 1 Oxidative stress ALS, PD
Insulin 1 Insulin resistance PD, MSA
Latrepirdine (dimebon) 5 Bioenergetic mitochondrial agent HD, AD
LMTM (TRx0237, LMT-X) 1 Tau aggregation FTLD, AD
Metformin 1 Insulin resistance FTLD, ALS
NBMI (N,N′-bis(2-mercaptoethyl) isophthalamide) 1 Mercury chelation (oxidative stress) PSP, MSA
Posiphen 1 Protein aggregation PD, AD
TPI-287 (abeotaxane) 1 Tau microtubule stabilizer CBD, PSP
Traneurocin (N-831) 1 Neurogenesis DLB, AD
Warfarin 1 Vascular (anticoagulant) AD, HD
Zoledronic acid 1 Bone loss prevention PD, DLB, PSP, MSA